Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial

Radiotherapy and Oncology

Volumn 91, Issue 1, 2009, Pages 120-125

  Hoskin, Peter J ^a,b   Rojas, Ana M ^b   Saunders, Michele I ^a,b,c   Bentzen, S M ^d   Motohashi, K J ^d  

^a CR UK Tumour Biology and Radiation Research Group   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Gray Cancer Institute   (United Kingdom)

Author keywords

Acute adverse events; Bladder; Carbogen; Nicotinamide; Toxicity

Indexed keywords

CARBOGEN; NICOTINAMIDE; RADIOSENSITIZING AGENT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANUS FISTULA; ARTICLE; BLADDER CANCER; BREATHING APPARATUS; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE REDUCTION; DYSURIA; FEMALE; FOLLOW UP; HEMATURIA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NAUSEA; PANIC; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; VOMITING;

AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CARCINOMA, TRANSITIONAL CELL; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NIACINAMIDE; OXYGEN; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 62549153550     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.001     Document Type: Article

References (22)

1. Shipley W.U., Zietman A.L., Kaufman D.S., Coen J.J., and Sandler H.M. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 15 (2005) 36-41
2. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6 (1994) 509-518
3. Chaplin D.J., Horsman M.R., and Aoki D.S. Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Brit J Cancer 63 (1991) 109-113
4. Kjellen E., Joiner M.C., Collier J.M., Johns H., and Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother Oncol 22 (1991) 81-91
5. Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Brit J Radiol 24 (1992) 174-178
6. Rojas A., Hirst V.K., Calvert A.S., and Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys 34 (1996) 357-365
7. Hoskin P.J., Rojas A.M., Phillips H., and Saunders M.I. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103 (2005) 2287-2297
8. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
9. Hoskin P.J., Rojas A.M., and Saunders M.I. Accelerated Radiotherapy, Carbogen and Nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II non-randomized study. Int J Radiat Oncol Biol Phys (2008) 10.1016/j.ijrobp.2008.06.195
10. Bernier J., Denekamp J., Rojas A., et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). Radiother Oncol 55 (2000) 111-119
11. Bernier J., Denekamp J., Rojas A., et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC. Radiother Oncol 52 (1999) 149-156
12. Miralbell R., Mornex F., Greiner R., et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 17 (1999) 3143-3149
13. Pickles T., Graham P., Syndikus I., et al. Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother Oncol 40 (1996) 245-247
14. Saunders M.I., Hoskin P.J., Pigott K., et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol 45 (1997) 159-166
15. Ruddock M.W., Burns D.M., Murphy L.E., O'Rourke M.G., and Hirst D.G. The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle. Radiother Oncol 56 (2000) 253-257
16. Bussink J., Stratford M.R., van der Kogel A.J., Folkes L.K., and Kaanders J.H. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother Oncol 63 (2002) 285-291
17. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
18. Chahal R., Sundaram S.K., Iddenden R., Forman D.F., Weston P.M., and Harrison S.C. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 43 (2003) 246-257
19. Cowan R.A., McBain C.A., Ryder W.D., et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 197-207
20. Horwich A., Dearnaley D., Huddart R., et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 75 (2005) 34-43
21. Pos F.J., van Tienhoven G., Hulshof M.C., Koedooder K., and Gonzalez Gonzalez D. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 68 (2003) 75-80
22. Yavuz A.A., Yavuz M.N., Ozgur G.K., et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56 (2003) 734-745